Edition:
United States

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

107.38USD
3:59pm EST
Change (% chg)

$7.00 (+6.97%)
Prev Close
$100.38
Open
$101.09
Day's High
$107.77
Day's Low
$100.68
Volume
237,757
Avg. Vol
111,637
52-wk High
$139.79
52-wk Low
$87.75

LGND.OQ

Chart for LGND.OQ

About

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science,... (more)

Overall

Beta: 1.26
Market Cap(Mil.): $2,097.96
Shares Outstanding(Mil.): 20.90
Dividend: --
Yield (%): --

Financials

  LGND.OQ Industry Sector
P/E (TTM): -- 44.08 29.63
EPS (TTM): -0.14 -- --
ROI: -0.72 -3.35 12.96
ROE: -0.78 5.80 14.11

BRIEF-Enrollment completed in Ligand's phase 2 trial of lgd-6972 in type 2 diabetes

* Enrollment completed in Ligand's phase 2 trial of lgd-6972 in type 2 diabetes

9:47am EST

BRIEF-Dr. Christel Iffland joins Ligand as vice president

* Dr. Christel Iffland joins Ligand as vice president, Antibody Technologies, expands team focused on OMNIAB drug discovery platform Source text for Eikon: Further company coverage:

Feb 14 2017

BRIEF-Ligand expects revenue related to Captisol material sales to be unchanged

* Ligand Pharmaceuticals - companies must adopt standard issued by FASB in may 2014 after january 1, 2017 and no later than january 1, 2018

Jan 18 2017

BRIEF-Ligand's partner Retrophin reports additional positive data from phase 2 duet study of sparsentan in focal segmental glomerulosclerosis at asn kidney week 2016

* Data shows statistically significant difference in modified partial remission; complete remission also observed

Nov 21 2016

BRIEF-Ligand Pharmaceuticals sees q4 2016 revenue $39 million to $43 million

* Q4 earnings per share view $1.37, revenue view $44.8 million -- Thomson Reuters I/B/E/S

Nov 03 2016

BRIEF-Ligand partner Melinta Therapeutics submits baxdela new drug application

* Ligand partner Melinta Therapeutics submits baxdela new drug application for hospital-treated skin infections

Oct 24 2016

BRIEF-Ligand Pharmaceuticals licenses four programs to Seelos Therapeutics

* Says under license agreement Ligand is entitled to receive an additional $3.5 million if Seelos becomes a public company

Sep 22 2016

BRIEF-Ligand enters OmniAb license agreement with TeneoBio inc

* Under license, TeneoBio will be able to use OmniFlic technology from OmniAb platform

Sep 16 2016

Retrophin kidney drug exceeds expectations in trial, shares jump

Retrophin Inc said its drug for a rare kidney disorder, which has no specific treatment, was found safe and effective in a mid-stage study, sending the company's shares soaring as much as 44 percent on Wednesday.

Sep 07 2016

UPDATE 3-Retrophin kidney drug exceeds expectations in trial, shares jump

* Retrophin shares rise as much as 44 pct (Adds details from conference call, analyst comment; updates shares)

Sep 07 2016

More From Around the Web

Earnings vs. Estimates